The Pharma Data

JANUARY 27, 2021

The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations, including but not limited to, (..)

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

NOVEMBER 15, 2020

The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations, including but not limited to, (..)

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

MAY 4, 2021

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., 7) BNT162b2 has not been approved or licensed by the U.S. Hospital products, which grew 10% operationally to $2.3

Vaccination 40

Vaccination Vaccine Production Sales 40